Transient HIV-1 Gag-protease interactions revealed by paramagnetic NMR suggest origins of compensatory drug resistance mutations Cleavage of the group-specific antigen (Gag) polyprotein by HIV-1 protease represents the critical first step in the conversion of immature noninfectious viral particles to mature infectious virions. Selective pressure exerted by HIV-1 protease inhibitors, a mainstay of current anti-HIV-1 therapies, results in the accumulation of drug resistance mutations in both protease and Gag. Surprisingly, a large number of these mutations (known as secondary or compensatory mutations) occur outside the active site of protease or the cleavage sites of Gag (located within intrinsically disordered linkers connecting the globular domains of Gag to one another), suggesting that transient encounter complexes involving the globular domains of Gag may play a role in guiding and facilitating access of the protease to the Gag cleavage sites. Here, using large fragments of Gag, as well as catalytically inactive and active variants of protease, we probe the nature of such rare encounter complexes using intermolecular paramagnetic relaxation enhancement, a highly sensitive technique for detecting sparsely populated states. We show that Gag-protease encounter complexes are primarily mediated by interactions between protease and the globular domains of Gag and that the sites of transient interactions are correlated with surface exposed regions that exhibit a high propensity to mutate in the presence of HIV-1 protease inhibitors.
HIV-1 Gag | HIV-1 protease | drug resistance mutations | invisible states | paramagnetic relaxation enhancement T he transformation of noninfectious viral particles into mature infectious virions is a hallmark of the retroviral replication cycle. In HIV type 1 (HIV-1), morphological remodeling is initiated on sequential hydrolysis of the group-specific antigen (Gag) polyprotein by the viral homodimeric aspartyl protease, which generates a set of structural proteins (1). Not surprisingly, therefore, HIV-1 protease inhibitors are major components of current anti-HIV-1 therapies (2). The organization of HIV-1 Gag is as follows: matrix (MA)-capsid (CA)-spacer peptide 1 (SP1)-nucleocapsid (NC)-spacer peptide 2 (SP2)-p6, with an HIV-1 protease cleavage site located at each junction (Fig. 1A) . MA, CA, and NC are globular domains, whereas SP1, SP2, and p6 are intrinsically disordered in solution (3). At neutral pH in vitro, the five cleavage sites in Gag are hydrolyzed by protease in the following order: SP1jNC > SP2jp6 ∼ MAjCA > CAjSP1 ∼ NCjSP2 (4). The corresponding in vivo cleavage order, deduced from virions with mutated Gag cleavage sites, is consistent with in vitro observations (5). The underlying mechanism governing ordered proteolysis is far from clear. Current understanding of Gag-protease interactions is derived from crystal structures of active protease complexed to nonhydrolysable peptide analogs (6) and of inactive protease (in which the active site Asp25 is replaced by Asn) bound to synthetic peptides comprising the Gag cleavage sites (7). Because all protease-bound peptides are in an extended, asymmetric β-strand conformation, it has been hypothesized that an effective protease substrate comprises six to eight residues of Gag (8) and that protease recognizes the shape of Gag substrates rather than their primary sequence (7). This "substrate envelope" hypothesis predicts variable interactions between side chains of Gag cleavage sites and protease (9), resulting in a unique processing rate for each site. Synthetic peptides, however, are a poor substitute for the Gag polyprotein in terms of long-range intermolecular interactions and conformational changes that can alter the accessibility of Gag cleavage junctions. Additionally both protease and Gag mutate and coevolve in response to protease inhibitors in current clinical use (10-17). Primary mutations (i.e., mutations at the catalytic site of protease) and mutations within the Gag cleavage sites are readily amenable to investigation using peptide analogs. The effects of secondary or compensatory mutations (i.e., mutations outside the protease substrate binding cleft or far away from the Gag cleavage sites), however, cannot be unraveled using synthetic peptides, and their existence hints at a larger role played by the globular Gag domains in Gag-protease interactions.
Here, using state-of-the-art solution NMR methods, and in particular intermolecular paramagnetic relaxation enhancement (PRE) measurements (18), we investigate Gag-protease interactions. We show that globular Gag domains transiently interact with protease to form sparsely populated encounter complexes, and that the patches of surface-exposed residues on the Gag domains and on protease that come into short-lived close contact with one another exhibit a high propensity to mutate in the presence of protease inhibitors.
Significance
Hydrolysis of group-specific antigen (Gag) polyprotein by protease is essential for the formation of infectious HIV-1 virions. In response to treatment with protease inhibitors, drug resistance mutations coevolve in protease and Gag, a significant number of which (known as compensatory mutations) lie outside the active site of protease and the Gag cleavage sites. We show, using paramagnetic NMR spectroscopy, that transient, sparsely populated encounter complexes are predominantly formed between the globular domains of Gag and protease at sites that correlate with the location of secondary drug resistance mutations. These results provide a structural basis for the origins of secondary mutations and suggest that transient encounter complexes play a significant role in guiding protease to the Gag cleavage sites.
Results
Gag and Protease Constructs. To elucidate the role of Gag domains in Gag-protease interactions, we made use of a large Gag fragment containing the MA-CA-SP1-NC domains (group M, residues 1-432, hereafter referred to as ΔGag; Fig. 1A ). ΔGag exhibits a monomer-dimer equilibrium at high ionic strength (K dimer ∼35 μM at ≥300 mM NaCl), but at low salt (≤100 mM NaCl) forms immature virus-like particles (3). We also made use of the construct, ΔGag W316A M317A (Fig. S1 ), which carries a double mutation at the CA dimerization interface and is monomeric at high (300 mM NaCl) ionic strength (Fig. S1A) , and the shorter construct CA-SP1-NC W316A M317A , which is monomeric at low (50 mM NaCl) ionic strength (Fig. S1B) . Protease from HIV-1 group O (PR-O, pI ∼5.2) was used instead of the more common M group (PR-M, pI ∼9.5, 70% sequence identity with PR-O), owing to its much better solubility properties at high ionic strength.
Ordered Proteolytic Cleavage of Gag. In vitro cleavage of ΔGag by PR-M proceeds in the following order: NCjSP1 > MAjCA > CAjSP1 (3). Nearly identical cleavage patterns, time courses, and proteolysis rates are observed using PR-O for both ΔGag and ΔGag W316A M317A (Fig. 1B, Fig. S2 , and Table S1 ), indicating that the order of Gag proteolysis is conserved across HIV-1 groups and is independent of Gag oligomerization state and protease isoelectric point. The order of cleavage is also not dependent on differences in amino acid sequence of the cleavage sites, as a similar sequential order of processing is observed for the construct ΔGag MAjCA=SP1jNC   CAjSP1=SP1jNC , in which the MAjCA and CAjSP1 cleavage  junctions (   128   VSQNYjPIVQN  137 and   359   KARVLjAEAMS   368 , respectively) were mutated to the same sequence as that of the SP1jNC cleavage site (   373   SATIMjMQRGN   383 ), although the cleavage rate at the CAjSP1 junction is now enhanced and comparable to that at the MAjCA junction (Fig. 1C) . These observations lead one to conclude that the globular Gag domains likely play a pivotal role in Gag-protease interactions.
Intermolecular PRE Measurements. To probe transient interactions between Gag and protease, we made use of NMR spectroscopy and specifically intermolecular PRE measurements (18). The intermolecular PRE arises from dipolar interactions between an unpaired electron located on a paramagnetic tag covalently attached to one protein and the protons of the second protein: in our case, backbone amide protons that can be selectively monitored by isotopically labeling the second protein with 15 N. When exchange between the unbound major species and the sparsely populated transient encounter complex is fast on the PRE time scale (lifetime < 250-500 μs), the intermolecular PRE observed on the protons of the major species will simply be given by the "true" intermolecular PRE within the complex scaled by the population of the complex (18). Owing to the large magnetic moment of the electron, the PRE effect (which is proportional to the <r
> separation between the unpaired electron and the proton) is very large, and hence transient complexes with occupancies as low as 0.5-1% can be detected (18).
We first carried out PRE experiments with the paramagnetic tag (maleimido-DOTA-Gd Fig. 2A ). Although the catalytic activity of the V82C variant of PR-O is reduced compared with the wild-type (WT) version, the order of Gag cleavage is preserved (Fig. S4) , and the structure of PR-O D25N V82C , determined from backbone amide residual dipolar couplings (RDCs) and backbone chemical shifts using 20) , is the same as that of PR-M with the flaps predominantly in the closed conformation (Fig. S5) Fig. 2 B and C. Very similar intermolecular PRE profiles are also observed for WT ΔGag, although line broadening owing to monomer-dimer exchange precludes the measurement of PREs for much of the capsid domain (Fig. S6) . Although the magnitude of the PREs may differ, the general pattern of intermolecular PREs obtained with the two paramagnetically tagged PR-O constructs is rather similar, with significant intermolecular PREs above background ) largely confined to specific surface-exposed regions within the three globular domains of Gag, namely MA, CA, and NC (Figs. 2 B-D) . These intermolecular PREs are specific to the Gag-protease system, as essentially no intermolecular PREs above background are observed in control experiments using either free DOTA-Gd 3+ or DOTA-Gd 3+ tagged maltose binding protein (MBP) (Fig. S7) . Interestingly, two regions display significant differences in intermolecular PREs between the ΔGag IMjMQRGN) . In all cases, Gag processing by PR-O occurs in the same sequential order. Cleavage rates obtained from analysis of the time courses of the SDS/ PAGE band intensities (see Fig. S2 and Table S1 ) are indicated. Aliquots of the reaction mixture at room temperature were taken at regular time intervals and visualized by PageBlue staining [18% (wt/vol) Tris-glycine gel]. The concentration of PR-O was 1 μM (in subunits), and the ratio of Gag to protease (in subunits) was 50:1 in B and 100:1 in C. Buffer conditions were as follows: 20 mM sodium phosphate, pH 6.5, 300 mM NaCl, 0.1 mM ZnCl 2 , and 1 mM TCEP.
NC domain and the negatively charged protease, which are magnified at low salt.
The unexpected absence of intermolecular PREs in the vicinity of the Gag cleavage sites can be attributed to two factors: (i) the occupancy of transient encounter complexes (lifetimes ≤ 250-500 μs probed by PRE) (18) involving the cleavage sites is much lower than that involving the globular domains of Gag; and (ii) the slow formation of weak (K D ∼300 μM) productive Gagprotease complexes are rate limited by protease flap opening (21, 22) . The flaps of free protease are predominantly closed (23), blocking access to substrate; flap opening is a rare process resulting in slow productive complex formation (lifetime ∼100 ms) (22), which is manifested by a significant reduction in 1 H N / 15 N cross-peak intensity for residues at the SP1jNC junction of ΔGag
W316A
M317A on addition of a 3:1 excess of unlabeled protease (Fig. S8A ). [Note that 1 H N / 15 N cross-peaks for residues at the MAjCA and CAjSP1 junctions are not affected at the concentrations of protease used, indicating that the SP1jNC junction serves as the primary point of association between Gag and protease, consistent with the observed order and rates of proteolytic cleavage (see Fig. 1B are colored in blue; residues that exhibit large PREs and are associated with drug resistance are depicted as dark blue spheres; those exhibiting large PREs only are shown as light blue spheres. Three residues (Thr186, Met200, and His219) in CA also associated with drug resistance (15, 16) are depicted as orange spheres; two of these (Thr186 and His219) give large PREs at low ionic strength (see C ), whereas Met200 is close to the patch of CA residues (residues 192-198) that exhibit large PREs at both high and low ionic strengths.
the MAjCA cleavage junction, was conjugated with DOTA-Gd 3+ (MA-CA C57T,C87 NTD ) (Fig. 3A) . In the second, monomeric ΔGag ) comprise residues near or in the catalytic site (residues 6-8 and 26-31), residues in the flaps (residues 46-53 and 82-83), and a small stretch of core residues (residues 88-94; Fig. 3B , Upper). With paramagnetically tagged ΔGag W316A M317A -d(TG) 4 , regions of protease exhibiting significant PREs include residues near or in the catalytic site (residues 5-10 and 23-29), the flaps (residues 30-43, 46-59, 71-77 and 80-83) , and part of the core (residues 64-66 and 87-97; Fig. 3B , Lower). Essentially no intermolecular PREs above background are observed on protease in control experiments using DOTA-Gd 3+ or Gd 3+ -tagged MBP (Fig. S9 ).
Discussion
Role of Gag-Protease Encounter Complexes. The observed pattern of intermolecular PRE profiles are indicative of the formation of transient encounter complexes involving the globular domains of Gag, which serve to guide protease in the vicinity of the Gag cleavage sites such that productive complex formation can occur efficiently on rare protease flap opening (Fig. 4) . These encounter complexes are likely to have a significant impact on the cleavage rates at the different Gag junctions. (It should be noted, however, that functional testing of the role of encounter complexes by in vitro mutagenesis is likely to be very difficult as the interfaces are relatively large and the contribution of any individual intermolecular interaction is likely to be very small. Hence, a large number of cumulative mutations would likely be required.) Other lines of biochemical evidence support this picture: the presence of single-stranded nucleic acids significantly accelerates hydrolysis at the SP1jNC junction while leaving the cleavage rate at the MAjCA and CAjSP1 unaltered (3). The two zinc knuckles of NC sample a large region of conformational space relative to one another in the absence of nucleic acids but behave as a single globular entity when bound to nucleic acids (24, 25), which would be predicted to enhance the formation of transient encounter complexes with protease. The two slowest cleavage sites (CAjSP1 and NCjSP2) occur at junctions that are not flanked by globular domains, suggesting that transient confinement of protease between Gag domains is important in sequential processing. A recent report (26) suggested that the six-helix bundle formed by SP1 (27) in immature Gag assemblies may block access to the CAjSP1 junction, thereby slowing down the proteolysis at this site. However, SP1 and neighboring residues are intrinsically disordered and fully accessible in solution in the context of ΔGag, as evidenced by NMR chemical shifts, relaxation parameters, and backbone amide RDCs (3, 24) , and yet hydrolysis at the CAjSP1 junction is remarkably slow in vitro (compare Fig. 1B ), even when mutated to the sequence of the SP1jNC junction (see Fig. 1C ). Moreover, of the five Gag cleavage sites, only the CAjSP1 and SP1jNC junctions, located a mere 15 residues apart, are interdependent on one another such that blocking hydrolysis at the SP1jNC junction by site-directed mutagenesis accelerates hydrolysis of the upstream CAjSP1 junction (4). These observations suggest that protease, guided by the CA and NC domains, can competitively interact with both cleavage junctions on either side of SP1, with an intrinsic preference for the SP1jNC junction. Based on these observations, we conclude that sequential in vitro hydrolysis of Gag is governed by several factors: transient interaction of Gag domains with protease, accessibility of Gag cleavage junctions, and the primary sequence of Gag cleavage sites. Moreover, because the sequential order of proteolytic processing is the same in vitro and in vivo, we speculate that these factors also dictate Gag hydrolysis in vivo. Additionally, steric hindrance due to the assembled Gag lattice and the protonation states of cleavage site residues are likely to also contribute to Gag processing in vivo.
Correlation of Sites of Encounter Complexes with Compensatory Drug
Resistance Mutations. A comparison of regions involved in transient Gag-protease encounter complexes with residues associated with drug-resistance mutations (14-17, 28) in Gag and protease is provided in Figs. 2D and 3C, respectively (also see Table S2 for additional details). The emergence of mutations resistant to HIV-1 protease inhibitors usually involves a stepwise process whereby primary mutations in protease alter the substrate-binding pocket leading to a reduction in inhibitor binding and concomitantly productive Gag-protease complex formation, whereas secondary or compensatory mutations in both protease and Gag may help partially restore the loss of viral fitness caused by the primary mutations (10, 15, 16) . The regions of Gag and protease that undergo compensatory mutations are strikingly similar to those exhibiting significant intermolecular PREs, thereby providing a plausible underlying structural basis behind these mutations. For example, conservative noncleavage site mutations in MA, specifically K30R, R76K, Y79F, and T81A, restore the fitness deficit arising from drug-resistant protease by improving replication capacity and generating a significant reduction in susceptibility to protease inhibitors in vivo (14, 29). These residues along with two other drug-resistance mutations, E12K and L75R, reside in regions of MA that give large intermolecular PREs. Similarly, among the few compensatory mutations in CA that have been reported, T186M and H219Q display large intermolecular PREs, whereas the third, M200I, is close to a region of CA that exhibits large . Further, several residues of NC mutate on exposure to protease inhibitors, and every single one displays large intermolecular PREs. It should also be noted that some of these residues are involved in other well-established functions [e.g., Lys30 and Arg76 of MA are involved in Gag-membrane interactions (30, 31), and His219 is located in an exposed loop within the N-terminal domain of CA loop that binds to cyclophilin-A (32)], implying multiple functions for these residues. The primary and secondary mutations in protease also show a close correlation with residues that exhibit significant intermolecular PREs, including residues in the core (residues 10, 71, 73, 88, 90, and 93) and flaps (residues 32-34, 36, 46, 47, 48, 50, 53, 54, and 82) . Based on the above correlations, we conclude that HIV-1 Gag-protease interactions have evolved a conserved mechanism whereby the globular domains of Gag act as guideposts for the formation of transient encounter complexes that facilitate access of the protease to the cleavage junctions, thereby enhancing cleavage rates and modulating the sequential order of Gag cleavage.
Materials and Methods
Protein Expression and Purification. Real-time NMR Fig. 4 . Schematic of the interactions of HIV-1 protease and Gag. Each illustrated step occurs at successively slower time scales that are accessible to different types of NMR measurements (as indicated in green). Transient encounter complexes, in fast exchange with the unbound species, are detected by PRE measurements (see Figs. 2 and 3 ). These ultra-weak complexes, involving quite extensive interactions surfaces, are initially formed and serve to guide the formation of productive complexes, thereby dictating the sequential order of Gag cleavage (i.e., we speculate that these transient encounter complexes accelerate the formation of productive complexes). The formation of productive complexes at the Gag cleavage sites are associated with rare conformational transitions involving flap opening (22, 23) that are detected by changes in cross-peak intensities and chemical shifts (intermediate exchange; see Fig. S8 ).
Finally, cleavage/liberation of individual MA, CA, and NC domains is a slow process that can be monitored by real-time NMR by observing site specific build-up of cross-peaks arising from the cleavage products (3).
buffer contained 300 and 50 mM NaCl in the case of ΔGag and CA-SP1-NC constructs, respectively.
NMR Spectroscopy. All heteronuclear NMR experiments were carried out at 30°C on Bruker 500-, 600-, and 800-MHz spectrometers equipped with z-gradient triple resonance cryoprobes. 4 , containing a single 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-Gd 3+ derivatized deoxythymidine, was purchased from Bio-Synthesis. ssDNA was dissolved in deionized water and dialyzed overnight (Spectra/Pro, Micro Float-A-Lyzer Dialysis Device; 100-to 500-Da cutoff, catalog no. F235049) in a buffer containing 20 mM sodium phosphate, pH 6.5, 300 mM NaCl, and 1 mM TCEP. Soluble paramagnetic cosolute, DOTA-Gd 3+ (also known as gadoteric acid) was purchased from Macrocyclics (catalog no. M-147) and dissolved in a buffer containing 50 mM sodium acetate, pH 6, to a final concentration of ∼10 mg/mL.
Protein Expression and Purification. WT and mutant variants of HIV-1 Gag polyprotein, ΔGag (MA-CA-SP1-NC, residues 1-432, strain HXB2, group M), CA-SP1-NC (residues 133-432, strain pLN4-3, group M), MA-CA NTD (residues 1-278, strain HXB2, group M), and HIV-1 protease (residues 1-99, group O), as well as apo-maltose binding protein (MBP), were subcloned into pET-11a vectors (Novagen; EMD Millipore) and expressed in BL21-CodonPlus (DE3)-RIPL competent cells (Agilent Technologies). Site-directed mutagenesis was performed using the QuikChange kit (Agilent Technologies).
ΔGag constructs were expressed at 19°C, whereas CA-SP1-NC and MA-CA NTD constructs were expressed at 37°C using our previously published protocols (3, 24) . Briefly, cells were grown at 37°C in 1 L Luria-Bertani (LB) medium at natural isotopic abundance or minimal M9 medium for isotopic labeling. N labeling. For ΔGag constructs, ∼30 min before induction, the temperature was reduced to 19°C. Cells were induced with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) at an optical density of A 600 ∼0.8. For CA-SP1-NC and MA-CA NTD constructs, the cells were harvested 8 h after induction, whereas for ΔGag constructs, the cells were harvested after 24 h. For HIV-1 protease, cells were grown at 37°C in 1 L of either LB or minimal M9 medium and were harvested 3 h after induction with IPTG. In the case of MBP, cells were grown at 37°C in 1 L LB medium and harvested 3 h after induction with IPTG.
For ΔGag and MA-CA NTD constructs, the cells were resuspended in a lysis buffer containing 100 mM Tris, pH 8.0, 500 mM NaCl, 5 mM β-mercaptoethanol (BME), and 1 cOmplete Protease Inhibitor mixture tablet (Roche Applied Science). For CA-SP1-NC constructs, the lysis buffer contained 100 mM Tris, pH 8.0, 50 mM NaCl, 0.1 mM ZnCl 2 , 5 mM BME, and 1 cOmplete tablet. Cells were lysed using a microfluidizer and cleared by centrifugation. Additionally, in the case of CA-SP1-NC constructs, nucleic acids were precipitated by adding 4% (wt/vol) polyethyleneimine, pH 8.0 (Sigma-Aldrich), to the cell lysate to a final concentration of ∼0.4% (wt/vol). All constructs were purified by a combination of ion exchange and size exclusion chromatography. For ΔGag and MA-CA NTD variants, the cell lysate was loaded onto a HiPrep 16/10 Q FF column (GE Healthcare) with a 0.5-1 M NaCl gradient in a buffer containing 100 mM Tris, pH 8.0, 500 mM NaCl, and 5 mM BME. For CA-SP1-NC constructs, a 0-1 M NaCl gradient was used with a running buffer containing 100 mM Tris, pH 8.0, 0.1 mM ZnCl 2 , and 5 mM BME. In the case of ΔGag and MA-CA NTD constructs, relevant flow-through fractions were diluted in a buffer containing 100 mM Tris, pH 8.0, and 5 mM BME (1:1 dilution), whereas for CA-SP1-NC constructs, the flow-through fractions were used without any further dilution. These fractions were loaded onto a HiLoad 16/10 SP Sepharose HP column (GE Healthcare) with a 0-1 M NaCl gradient containing 100 mM Tris, pH 8.0, and 5 mM BME. The eluted proteins were concentrated (Amicon ultra-15, 10-kDa cutoff for MA-CA NTD and CA-SP1-NC constructs, and 30-kDa cutoff for ΔGag constructs) and loaded onto a HiLoad 26/60 Superdex 200 column (GE Healthcare) pre-equilibrated with 100 mM Tris, pH 8, 500 mM NaCl, and 5 mM BME. For CA-SP1-NC and MA-CA NTD constructs, a HiLoad 26/60 Superdex 75 column (GE Healthcare) was used pre-equilibrated with 100 mM Tris, pH 8, 300 mM NaCl, and 5 mM BME. Relevant fractions were pooled and diluted in a buffer containing 20 mM Tris, pH 8.0, and 5 mM BME (1:1 dilution), and further purified using a Mono S 10/100 GL column (GE Healthcare) with a 0-1 M NaCl gradient. Note that for ΔGag and CA-SP1-NC constructs, every buffer solution was supplemented with 0.1 mM ZnCl 2 .
For WT active protease-O (PR-O), the cells were resuspended in a bacterial protein extraction reagent (ThermoFisher; catalog no. 78248) supplemented with 5 mM benzamidine. Cells were lysed using a sonicator and cleared by centrifugation. Ammonium sulfate was added to the supernatant to a final concentration ∼20% (wt/vol) and incubated at room temperature followed by centrifugation. The pellet was resuspended in buffer containing 25 mM Tris, pH 7.5, 50 mM NaCl and spun, and the supernatant subjected to fractionation on a HiLoad 16/60 Superdex 75 column (GE Healthcare) pre-equilibrated with 25 mM Tris, pH 7.5, and 50 mM NaCl. Peak fractions corresponding to active PR-O were pooled, concentrated (Amicon ultra-15, 10-kDa cutoff), and stored at −70°C.
In the case of the two PR-O variants, PR-O D25N L72C and PR-O D25N V82C , the proteins were purified using the following two schemes. For unlabeled proteins, the cells were resuspended in buffer containing 50 mM Tris, pH 8, 10 mM EDTA, 10 mM DTT, and ∼100 μg/mL lysozyme. The insoluble recombinant protein was washed using a buffer containing 50 mM Tris, pH 8, 10 mM EDTA, 10 mM DTT, 2 M urea, and 1% (vol/vol) Triton X-100. The insoluble fraction was pelleted by centrifugation and solubilized in 50 mM Tris, pH 8.0, 7.5 M guanidine hydrochloride, 5 mM EDTA, and 10 mM DTT. The solubilized fraction was injected on a HiLoad 16/60 Superdex 75 column (GE Healthcare) pre-equilibrated in 50 mM Tris, pH 8, 4 M guanidine hydrochloride, 5 mM EDTA, and 1 mM DTT. Eluted fractions were pooled and subjected to reverse-phase HPLC on a POROS R2 20-μm resin (ThermoFisher; catalog no. 1112906). Peak fractions were pooled and stored at −70°C. For the 2 H/ 15 N-labeled PR-O variants, a similar protocol was used except that the supernatant fraction, instead of the insoluble fraction, was stirred for 1 h at room temperature in the presence of 20% (wt/vol) ammonium sulfate, followed by centrifugation. The pellet was resuspended in 25 mM Tris, pH 7.5, and 50 mM NaCl and spun. The supernatant was adjusted to 2 M guanidine hydrochloride and concentrated (Amicon ultra-15, 10-kDa cutoff). Proteins were fractionated using size-exclusion chromatography and reversephase HPLC as described above.
To fold PR-O samples, aliquots were lyophilized and later redissolved in 4 M guanidine hydrochloride, 50 mM Tris, pH 7.5, and 2 mM DTT to a final concentration of ∼5 mg/mL, followed by extensive dialysis in aqueous buffers without guanidine hydrochloride.
For apo-maltose binding protein, the cells were resuspended in a lysis buffer containing 100 mM Tris, pH 8.0, 500 mM NaCl, 1 mM EDTA, and 5 mM BME. Cells were lysed using a microfluidizer, cleared by centrifugation, and then loaded onto an Amylose resin column (New England BioLabs) with a 0-10 mM maltose gradient containing 100 mM Tris, pH 8.0, 500 mM NaCl, 1 mM EDTA, and 5 mM BME. The eluted protein was concentrated (Amicon ultra-15, 10-kDa cutoff) and loaded onto a HiLoad 26/60 Superdex 75 column (GE Healthcare) pre-equilibrated with 100 mM Tris, pH 8, and 500 mM NaCl.
All protein constructs were verified by DNA sequencing and mass spectrometry.
Site-Specific Spin Labeling with Gd
3+
. The commercially available paramagnetic probe, maleimido-monoamide-DOTA (Macrocyclics: catalog no. B-272; 1,4,7,10-tetraazacyclododecane-1,4,7-tris(t-butyl-acetate)-10-(aminoethylacetamide)), was mixed with Gd(III) chloride hexahydrate (Sigma-Aldrich; catalog no. G7532) at a molar ratio 1:2 in 50 mM sodium acetate buffer, pH 5.5. The mixture was incubated overnight at room temperature, and the reaction was verified by mass spectrometry. The resultant complex was purified by reverse-phase HPLC (Beckman Ultrasphere ODS column, MAC-MOD Analytical; catalog no. 235328). Relevant fractions were pooled, lyophilized, and later redissolved in 50 mM sodium acetate buffer, pH 6.0. For site-specific paramagnetic spin labeling, a DOTA-Gd 3+ stock solution (∼8 mg/mL) was incubated for 1 h at room temperature with the protein of interest (Gag, MBP, or PR-O variants containing a single surface-exposed cysteine residue) at a molar ratio of protein to paramagnetic label of ∼1:1.2 in 100 mM Tris, pH 8. The conjugation reaction was tested for completion by mass spectrometry, and excess unreacted paramagnetic spin-label was removed by dialysis (Slide-A-Lyzer G2 Dialysis Cassettes; ThermoFisher Scientific). All buffers were treated with chelex-100 (Sigma-Aldrich; catalog no. 88593) to remove any potential trace metal contamination.
Sedimentation Velocity Analytical Ultracentrifugation. Sedimentation velocity experiments were conducted at 50,000 rpm using an An50-Ti rotor (Beckman Coulter) on a Beckman Coulter ProteomeLab XL-I analytical ultracentrifuge following protocols described previously (33). Samples of ΔGag
W316A
M317A were studied at loading concentrations ranging from 2.5 to 66 μM in 20 mM sodium phosphate, pH 6.5, 300 mM NaCl, 1mM TCEP, and 0.1 mM ZnCl 2 and 30°C. Samples of CA-SP1-NC W316A M317A were studied at 20°C and loading concentrations of 10-84 μM in 20 mM sodium phosphate (pH 6.5), 50 mM NaCl, 1 mM TCEP, and 0.1 mM ZnCl 2 . Samples were loaded in two-channel centerpiece cells, and data were collected using the absorbance (280 nm) and Rayleigh interference (655 nm) optical detection systems. In both cases, the highest concentration samples were loaded in 3-mm pathlength cells, whereas all other samples were loaded in standard 12-mm path-length cells. Sedimentation data were timecorrected (34) and analyzed in SEDFIT15.01c (35) in terms of a continuous c(s) distribution of Lamm equation solutions with a resolution of 0.05 S and a maximum entropy regularization confidence level of 0.68. Excellent data fits were observed, with RMSD values ranging from 0.0037 to 0.0079 absorbance units and 0.0060 to 0.011 fringes. The solution densities and viscosities were determined based on the buffer composition in SEDNTERP (36) (sednterp.unh.edu). Protein partial specific volumes were calculated based on the amino acid composition in SEDNTERP, and sedimentation coefficients s were corrected to s 20,w values at standard conditions. NMR Spectroscopy. All heteronuclear NMR experiments were carried out at 30°C on Bruker 500-, 600-, and 800-MHz spectrometers equipped with z-gradient triple resonance cryoprobes. Spectra were processed using NMRPipe (38) and analyzed using the CCPN software suite (39). Sequential J NH coupling constants in aligned and isotropic media) were measured using the TROSY-based ARTSY pulse sequence (41) and analyzed with Xplor-NIH (42). Transverse 1 H N -Γ 2 PRE rates were obtained from the differences in the transverse 1 H N -R 2 relaxation rates between the paramagnetic and diamagnetic samples (18, 43) . Two time points (separated by 15 ms) were used for the measurements of 1 H N -R 2 rates, and the errors in the 1 H N -Γ 2 PRE rates were calculated as described previously (18, 43) . The transverse 1 H N -R 2 relaxation rates were measured using 3D HNCO-based (44) and 2D (18) pulse schemes with TROSY readout for ΔGag and CA-SP1-NC/protease constructs, respectively. TROSY 1 H-15 N correlation spectra of the proteins were recorded before and after the PRE experiments to verify that no spurious intermolecular disulfides were formed during the course of the measurements.
ΔGag Cleavage Assay. ΔGag hydrolysis was carried out using our previously published protocol (3). Briefly, ΔGag constructs were incubated for 3 h at room temperature with 1 μM PR-O variants in a buffer containing 20 mM sodium phosphate, pH 6.5, 300 mM NaCl, 0.1 mM ZnCl 2 , and 1 mM TCEP. Aliquots (5 μL each) were taken at regular time intervals, mixed with SDS protein gel loading solution (Quality Biological; , boiled at 99°C for 2 min, and loaded onto a SDS/PAGE gel [18% (wt/vol) Tris-glycine gel; Life Technologies; catalog no. EC65055BOX]. Cleavage products were visualized by PageBlue staining (ThermoFisher Scientific; catalog no. 24620). M317A confirm that these constructs are entirely monomeric. Note that the highest concentration data (blue curves) were collected using 3-mm path-length cells. Identical profiles were obtained with the interference optical detection system. The buffer used comprised 20 mM sodium phosphate, pH 6.5, 1 mM TCEP, and 0.1 mM ZnCl 2 ; the ΔGag W316A M317A sample also contained 300 mM NaCl, whereas the CA-SP1-NC W316A M317A sample contained 50 mM NaCl.
Time ( 
MAjCA=SP1jNC
CAjSP1=SP1jNC at molar ratios (in subunits) of 50:1, 50:1, and 100:1, respectively, Gag to protease. The concentration of PR-O was 1 μM (in subunits). The apparent rate constants, k SP1jNC , k MAjCA, and k CAjSP1 , are the rates of proteolysis at the SP1jNC, MAjCA, and CAjSP1 cleavage junctions, respectively. Experimental data are shown as circles, whereas the best-fit curves are shown by the continuous lines. The 1D gel analysis module from ImageQuant TL (GE Healthcare) was used to determine band intensities in SDS/PAGE gels (see Fig. 1 B and C) , and the cleavage rates were obtained by nonlinear least squares fitting and solving the appropriate simultaneous first-order ordinary differential equations using the program DyanaFit (45). The color scheme is as follows: ΔGag, blue; intermediates, MA-CA-SP1 + MA-CA, red, CA-SP1-NC, green, CA-SP1, magenta; final products: CA, lilac, MA, brown, and NC, black. In the case of the ΔGag
CAjSP1=SP1jNC variant, the SDS/PAGE bands for the intermediates, MA-CA-SP1 and MA-CA, can be resolved (see Fig. 1C ) and are depicted in red and gray, respectively. , is covalently attached to the protein of interest via a single surface-exposed cysteine residue using a chemo-specific reaction involving the formation of a S-C bond between the maleimide moiety of the probe and the thiol functional group of the cysteine. A DOTA-Gd 3+ stock solution was incubated with the protein of interest for 1 h at room temperature at a protein to tag molar ratio of ∼1:1.2. The buffer conditions were as follows: 100 mM Tris, pH 8. See SI Materials and Methods for additional details. (B) DNA labeling. The DOTA-Gd 3+ paramagnetic tag is covalently attached via a linker to a thymine base by a C=C double bond involving the methyl carbon. In this instance the paramagnetic label was attached to the third base of the 8mer single stranded (TG) 4 DNA (the asterisk indicates the site of labeling) purchased from Biosynthesis and purified as described in SI Materials and Methods. Note that despite the 3-h incubation of ΔGag with PR-O V82C , the primary cleavage product from the hydrolysis at the CAjSP1 junction, namely CA, is not observed, making it difficult to quantitate the rate of CAjSP1 cleavage, other than to note that it is extremely slow compared with the other two cleavages (marked in blue). Buffer conditions were as follows: 20 mM sodium phosphate, pH 6.5, 300 mM NaCl, 0.1 mM ZnCl 2 , and 1 mM TCEP. (B) Quantitative analysis of ΔGag cleavage by PR-O V82C . The apparent rate constants k SP1jNC and k MAjCA are Gag proteolysis rates (pmol/min) at the SP1jNC and MAjCA cleavage junctions, respectively. Experimental data are depicted as circles and the best-fit curves by continuous lines (see Fig. S2 and Table S1 for further details). The color scheme is as follows: ΔGag, blue; intermediates: CA-SP1-NC, green, and CA-SP1, magenta; final products: MA, brown, and NC, black. , where D obs and D calc are the observed and calculated RDC values, respectively (50). Buffer and experimental conditions were as follows: 20 mM sodium phosphate, pH 6.5, 300 mM NaCl, 0.1 mM ZnCl 2 , 1 mM TCEP, and 30°C. ) are delineated by transparent gray bars. A few of the residues that exhibit large PREs and undergo drug-resistant mutations are labeled with the latter in bold italics. Buffer and experimental conditions were as follows: 20 mM sodium phosphate, pH 6.5, 300 mM NaCl, 0.1 mM ZnCl 2 , and 30°C. The concentration of protease was 100 μM (in subunits) with a 3:1 molar ratio of Gag to protease. Severe resonance line broadening of resonances as a consequence of monomer-dimer exchange of the CA CTD results in far fewer PRE data points within the capsid region of WT ΔGag compared with the monomeric variant ΔGag (at residues  194 HQA 196 , R286, G357, G412) are observed with DOTA-Gd 3+ owing to random collisions at solvent-exposed, surface accessible sites; these solvent PREs are much reduced ( 1 H N -Γ 2 ≤ 10 s −1 ) with MBP E38C -DOTA-Gd 3+ , as the larger size of MBP (∼40 kDa) precludes preferential access to these sites. All PREs observed with either DOTA-Gd 3+ or MBP E38C -DOTA-Gd 3+ (gray bars) are much smaller than those observed with PR-O D25N V82C -DOTA-Gd 3+ (red bars). Gag cleavage sites are marked by vertical dashed lines and scissors. The numbers in circles indicate the order in which each site is cleaved with the SP1jNC site being the first cleaved. Buffer and experimental conditions were as follows: 20 mM sodium phosphate, pH 6.5, 50 mM NaCl, 0.1 mM ZnCl 2 , and 30°C. The concentration of CA-SP1-NC . PR-O residues that exhibit a large reduction in cross-peak intensity on addition of ΔGag W316A M317A are marked with blue circles. Buffer and experimental conditions were as follows: 20 mM sodium phosphate, pH 6.5, 300 mM NaCl, 0.1 mM ZnCl 2 , 1 mM TCEP, and 30°C. The concentration of isotopically labeled protein was 50 μM with a molar ratio of unlabeled to isotopically labeled protein of 3:1 (in subunits). ). Negligible intermolecular PREs are observed with soluble DOTA-Gd 3+ with the exception of Gly40, which is highly solvent exposed (B). The same region (residues 39-41) also exhibits a noticeable intermolecular PRE effect in the presence of d(TG) 4 -DOTA-Gd 3+ (C). Based on the fact that the PREs observed with the paramagnetically tagged Gag variants are much larger than and distinct from those for the negative controls, we conclude that the former arise from transient encounter complexes between PR-O and Gag polyproteins. Buffer and experimental conditions were as follows: 20 mM sodium phosphate, pH 6.5, 0.1 mM ZnCl 2 , and 30°C; 50 mM NaCl was used in A and B and 300 mM in C. The concentration of 
